Kajian efek interaksi antihipertensi dengan obat antiinflamasi nonsteroid (OAINS) terhadap tekanan darah pada pasien hipertensi
DOI:
10.29303/sjp.v5i1.235Downloads
Abstract
Hypertension causes atherosclerosis which can cause occlusion resulting in subchondral ischemia, which causes the exchange of nutrients and gases into the articular cartilage, which is disrupted and becomes the potential initiator of degradative changes or the so-called osteoarthritis. This review aims to evaluate the effect of antihypertensive drug interactions with NSAIDs on blood pressure. This article review was conducted using a narrative review study. The inclusion criteria in this article are the pharmacodynamic interaction of antihypertensives with NSAIDs in hypertensive patients with osteoarthritis. The results obtained seven articles that meet the inclusion criteria. Hypertensive patients with osteoarthritis receive medications that must be monitored because a drug-drug interaction can decrease the effectiveness of antihypertensives. One of the most widely used drugs in antihypertensive therapy is ACEi, but NSAIDs inhibit the antihypertensive effect on prostaglandin synthesis resulting from bradykinin production. The decrease in blood pressure stimulated by bradykinin plays an essential role in vasodilatation. The interaction of ACEi and NSAIDs can cause an increase in blood pressure with a minimum expansion of 1.1 mmHg. Still, when administering NSAIDs with CCBs, a decrease in blood pressure of 2.86 mmHg is obtained because the action is not dependent on prostaglandins. Based on the results, there were pharmacodynamic changes for both antihypertensive drugs and NSAIDs due to drug interactions that affected the patient's clinical outcome in the form of blood pressure.
Keywords:
Antihypertensive, Hypertension, Interaction, NSAIDs, Osteoarthritis, PharmacokineticsReferences
Akbar, H., & Santoso, E. B. (2019). Faktor risiko kejadian osteoarthritis lutut di Rumah Sakit Umum Haji Surabaya. PROMOTIF: Jurnal Kesehatan Masyarakat, 9(2), 219–224. https://doi.org/https://doi.org/10.56338/pjkm.v9i2.974
Aljadhey, H., Tu, W., Hansen, R. A., Blalock, S. J., Brater, D. C., & Murray, M. D. (2012). Comparative effects of non-steroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension. BMC Cardiovascular Disorders, 12, 93. https://doi.org/10.1186/1471-2261-12-93
Baxter, K. (2010). Stockley’s Drug Interactions Ed 9, Pharmaceutical Press.
Faizah, A. K., & Nurrahman, N. W. D. (2020). Evaluation of Potential Drug-Drug Interactions in Hypercholesterolemia Patients at Teaching Hospital Surabaya, in Proceedings of the 4th International Conference on Sustainable Innovation 2020–Health Science and Nursing (ICoSIHSN 2020), 2021, vol. 33. doi: 10.2991/ahsr.k.210115.064.
Goswami, S. K., Goswami, S. S., Patil, C. R., & Santani, D. D. (2020). Study of Enalapril and Diclofenac Sodium in Osteoarthritic Hypertensive Patients. Journal of Medical Science and Clinical Research, 08(05), 35–44. https://doi.org/10.18535/jmscr/v8i5.05
Gradman, A. H., Basile, J. N., Carter, B. L., & Bakris, G. L. (2011). Combination therapy in hypertension. The Journal of Clinical Hypertension, 13(3), 146–154. https://doi.org/10.1111/j.1751-7176.2010.00397.x
Gualtierotti, R., Zoppi, A., Mugellini, A., Derosa, G., D'Angelo, A., & Fogari, R. (2013). Effect of naproxen and acetaminophen on blood pressure lowering by ramipril, valsartan and aliskiren in hypertensive patients. Expert opinion on pharmacotherapy, 14(14), 1875–1884. https://doi.org/10.1517/14656566.2013.816286
Kalafutova, S., Juraskova, B., & Vlcek, J. (2014). The impact of combinations of non-steroidal anti-inflammatory drugs and anti-hypertensive agents on blood pressure. Advances in clinical and experimental medicine: official organ Wroclaw Medical University, 23(6), 993–1000. https://doi.org/10.17219/acem/37357
Landefeld, K., Gonzales, H., & Sander, G. E. (2016). Hypertensive crisis: The causative effects of Nonsteroidal Anti-Inflammatory Drugs. Journal of Clinical Case Reports, 6(7), 10–12. https://doi.org/10.4172/2165-7920.1000838
MacDonald, T. M., Richard, D., Lheritier, K., & Krammer, G. (2010). The effects of lumiracoxib 100 mg once daily vs. ibuprofen 600 mg three times daily on the blood pressure profiles of hypertensive osteoarthritis patients taking different classes of antihypertensive agents. International journal of clinical practice, 64(6), 746–755. https://doi.org/10.1111/j.1742-1241.2010.02346.x
Mahamudu, Y. S., Citraningtyas, G., & Rotinsulu, H. (2017). Kajian Potensi Interaksi Obat Antihipertensi Pada Pasien Hipertensi Primer Di Instalasi Rawat Jalan RSUD Luwuk Periode Januari – Maret 2016. Pharmacon, 6(3), 1-9.
Nikiforov, R.V., Shevcova, V.I., Zuykova, A.A. (2019). Evaluation Of Prohypertensive Effect Of Meloxicam On The Blood Pressure Indicators. The Russian Archives of Internal Medicine, 9(1), 60-63, doi: 10.20514/2226-6704-2019-9-1-60-63.
Pavlicević, I., Glavaski, M., Rumboldt, M., & Rumboldt, Z. (2011). Prohypertensive effects of non-steroidal anti-inflammatory drugs are mostly due to vasoconstriction. Collegium antropologicum, 35(3), 817–822.
Raman, R. B., Khare, A. K., Kumar, D., Ghosh, D., Tripathi, N., Srivastava, D., Prakash, V., & Saurabh, S. (2019). Open label case control prospective study to evaluate the impact of aceclofenac on antihypertensive action of amlodipine and ramipril in hypertensive patients with osteoarthritis. International Journal of Medical Research and Review, 7(1), 43–49. https://doi.org/10.17511/ijmrr.2019.i01.08
World Health Organization. (2013). A global brief on hypertension: Silent killer, global public health crisis. https://www.who.int/publications/i/item/a-global-brief-on-hypertension-silent-killer-global-public-health-crisis-world-health-day-2013
Zahra, A. P., & Carolia, N. (2017). Obat Anti-inflamasi Non-steroid (OAINS): Gastroprotektif vs kardiotoksik. Majority, 6(3), 153–158.
License
Copyright (c) 2024 The Author(s)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with Sasambo Journal of Pharmacy (SJP), agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Lisensi Creative Commons Atribusi 4.0 Internasional. This license allows authors to use all articles, data sets, graphics and appendices in data mining applications, search engines, web sites, blogs, and other platforms by providing an appropriate reference. The journal allows the author(s) to hold the copyright without restrictions and will retain publishing rights without restrictions.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Sasambo Journal of Pharmacy
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
